Literature DB >> 1867172

How are antineutrophil cytoplasmic autoantibodies detected?

J Wieslander1.   

Abstract

Antineutrophil cytoplasmic autoantibodies (ANCA) are present in patients with systemic vasculitis with or without renal involvement. These antibodies were first seen using indirect immunofluorescence (IIF). Two types of patterns are seen on ethanol-fixed neutrophils: the cytoplasmic and the perinuclear pattern. The cytoplasmic pattern is called C-ANCA (classical or cytoplasmic ANCA) and the perinuclear, P-ANCA. Antibodies to a serine proteinase, called proteinase 3 or myeloblastin, give rise to the C-ANCA pattern, while antibodies to myeloperoxidase give rise to the P-ANCA pattern. Proteinase 3, as well as myeloperoxidase, is present in the primary granules of neutrophils, and the P-ANCA pattern is thus an artifactual staining pattern. Myeloperoxidase, which is a basic protein, redistributes during ethanol fixation from the primary granules to the negatively charged nucleus. As an alternative to the IF technique, several solid-phase assays have been developed using either 125I or enzyme-labeled secondary antibodies. Depending on the degree of purification of the antigens used, such assays may be used for screening or as a complement to the IF method. Today it is possible to directly screen for both types of ANCA using enzyme-linked immunosorbent assay (ELISA). Simultaneous screening for antiglomerular basement membrane (GBM) antibodies (Goodpasture antibodies) increases the diagnostic yield, especially in patients with renopulmonary syndromes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867172     DOI: 10.1016/s0272-6386(12)80872-9

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

3.  ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis.

Authors:  A Harris; G Chang; M Vadas; D Gillis
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

Review 4.  The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA).

Authors:  X Bosch; R A Asherson
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 5.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 6.  Anti-neutrophil cytoplasmic autoantibodies (ANCA) and vasculitis.

Authors:  B Baslund; A Wiik
Journal:  Clin Rev Allergy       Date:  1994

7.  The absence of anti-neutrophil cytoplasmic antibodies in patients with Henoch-Schönlein purpura.

Authors:  W L Robson; A K Leung; R C Woodman
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

8.  Anti-neutrophil cytoplasmic auto-antibodies-associated vasculitis with pulmonary and renal involvement.

Authors:  G Pintos-Morell; A Roca-Comas; M A Naranjo; C Tural; E Abad; G Javier; J Prats
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

9.  Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.

Authors:  Mårten Segelmark; Brian D Phillips; Susan L Hogan; Ronald J Falk; J Charles Jennette
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in children.

Authors:  M C Nash; C L Jones; R G Walker; H R Powell
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.